Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
Marlana Orloff Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA Abstract: On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melan...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-10-01
|
| Series: | Oncolytic Virotherapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spotlight-on-talimogene-laherparepvec-for-the-treatment-of-melanoma-le-peer-reviewed-article-OV |